A股異動 | 億帆醫藥一度漲8% 控股子公司簽署獨家許可協議 獲不超2.37億美元
格隆匯11月15日丨億帆醫藥(002019.SZ)盤初一度漲至8%,現報12.99元再度刷新階段高價,總市值160億元。公司控股子公司美國億一同意將在研產品F-627在美國的獨家經銷權許可給ACROTECH公司,ACROTECH公司以此獲得在合作區域內的獨家銷售權,ACROTECH公司需要向美國億一支付最高額不超過2.37億美元的獨家許可費(首付款、里程碑付款),以及兩位數的分級淨銷售額提成費。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.